JP2015518819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518819A5 JP2015518819A5 JP2015511675A JP2015511675A JP2015518819A5 JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5 JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015511675 A JP2015511675 A JP 2015511675A JP 2015518819 A5 JP2015518819 A5 JP 2015518819A5
- Authority
- JP
- Japan
- Prior art keywords
- viral protein
- protein complex
- animal
- viral
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| US61/644,830 | 2012-05-09 | ||
| PCT/US2013/040228 WO2013169961A1 (en) | 2012-05-09 | 2013-05-09 | Conformationally specific viral immunogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Division JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015518819A JP2015518819A (ja) | 2015-07-06 |
| JP2015518819A5 true JP2015518819A5 (enExample) | 2016-06-30 |
Family
ID=49548782
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20130302366A1 (enExample) |
| EP (2) | EP3483174A1 (enExample) |
| JP (4) | JP2015518819A (enExample) |
| AU (5) | AU2013259548A1 (enExample) |
| CA (1) | CA2873048C (enExample) |
| IN (1) | IN2014DN09445A (enExample) |
| WO (1) | WO2013169961A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3024483B1 (en) | 2013-07-25 | 2020-01-15 | Calder Biosciences Inc. | Conformationally stabilized rsv pre-fusion f proteins |
| EP3027640B1 (en) | 2013-08-03 | 2018-03-07 | Avatar Medical, LLC | Influenza hemagglutinin proteins and methods of use thereof |
| AU2018313000B2 (en) | 2017-08-07 | 2025-07-03 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| WO2019178521A1 (en) | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| WO2021231651A2 (en) * | 2020-05-12 | 2021-11-18 | The Regents Of The University Ofcalifornia | Sars-cov2 neutralizing single domain antibody constructs |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| JP2003511420A (ja) * | 1999-10-13 | 2003-03-25 | カイロン コーポレイション | タンパク質から細胞性免疫応答を得る方法 |
| ES2367475T3 (es) | 1999-10-15 | 2011-11-03 | Avatar Medical, L.L.C. | Proteínas estabilizadas. |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| EP1463521A4 (en) | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | INHIBITOR OF GP41 |
| US20080206264A1 (en) | 2003-02-04 | 2008-08-28 | New York University | Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists |
| US20050054572A1 (en) * | 2003-07-03 | 2005-03-10 | Marshall Christopher P. | Methods for obtaining molecules with reduced immunogenicity |
| WO2005118886A2 (en) * | 2004-06-01 | 2005-12-15 | Merck & Co., Inc. | Stable peptide mimetic of hiv gp41 fusion intermediate |
| WO2007149491A2 (en) * | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CN105566450A (zh) * | 2007-07-27 | 2016-05-11 | 伊玛提克斯生物技术有限公司 | 免疫疗法的新型免疫抗原表位 |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| SMT202000101T1 (it) * | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| US20110123556A1 (en) | 2009-11-24 | 2011-05-26 | Sanjay Phogat | Immunogen prioritization for vaccine design |
| EP2572196A4 (en) | 2010-05-18 | 2014-04-23 | Christopher P Marshall | ANTIGEN IDENTIFICATION TEST THAT ACTIVATES B-CELL RECEPTORS COMPRISING NEUTRALIZING ANTIBODIES |
| US20130149336A1 (en) * | 2011-10-27 | 2013-06-13 | Brian L. Hjelle | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries |
| EP2804948B1 (en) | 2012-01-20 | 2020-04-15 | The Government of The Hong Kong Special Administrative Region of The People's Republic of China | A novel paramyxovirus and uses thereof |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en not_active Ceased
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/en active Pending
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/en not_active Not-in-force
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en not_active Ceased
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja not_active Expired - Fee Related
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2023
- 2023-08-25 US US18/455,787 patent/US20240238369A1/en not_active Abandoned
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fougeroux et al. | Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity | |
| Liu et al. | Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical ferret model | |
| MX375379B (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| JP2015518819A5 (enExample) | ||
| Tan et al. | Recent advancements in combination subunit vaccine development | |
| JP2020125323A5 (enExample) | ||
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| JP2014530010A5 (enExample) | ||
| Vemula et al. | Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness | |
| Szécsi et al. | Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses | |
| JP2014237714A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| Xu et al. | Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines | |
| Verma et al. | Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies | |
| MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| Du et al. | Flu universal vaccines: new tricks on an old virus | |
| JP2013523783A5 (enExample) | ||
| Ellis et al. | Antigen spacing on protein nanoparticles influences antibody responses to vaccination | |
| Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
| Khurana et al. | H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine | |
| Brinkkemper et al. | Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses | |
| JP2022078254A5 (enExample) | ||
| Hassan et al. | Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses | |
| Cunha et al. | Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers | |
| Sigoillot-Claude et al. | A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine |